Stargardt's Disease
6
2
3
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
16.7%
1 terminated out of 6 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Rod and Cone Mediated Function in Retinal Disease
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration
Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration
Stem Cell Therapy for Outer Retinal Degenerations
Microcurrent Stimulation to Treat Macular Degeneration